Thymosin Alpha-1 Reconstitution Chart (Every Vial Size)

Overview of Lyophilized Thymosin Alpha-1 Reconstitution

Thymosin Alpha-1 (TA1) is a 28-amino-acid synthetic peptide fragment derived from prothymosin alpha, widely studied in preclinical immunology and cell culture models. Supplied as a highly purified, lyophilized powder, the peptide requires careful volumetric reconstitution with sterile laboratory solvents prior to experimental execution. Reconstitution converts the stabilized solid cake into a biological solution with a known target concentration, measured in milligrams per milliliter (mg/mL) or micrograms per microliter (µg/µL).

Because laboratory experiments require strict stoichiometry—whether dosing microfluidic chambers, culturing primary lymphocytes, or establishing baseline concentrations for animal studies—calculating the exact concentration of reconstituted stock solution is mandatory. Imprecise reconstitution leads to volumetric drift, experimental variation, and non-reproducible analytical assay data. Laboratories utilizing research peptides rely on standardized reference charts to eliminate conversion errors and ensure lot-to-lot consistency.

Thymosin Alpha-1 Reconstitution Chart Matrix

The following reference matrix outlines the resulting target concentrations when reconstituting common vial sizes of Thymosin Alpha-1—including 2 mg, 5 mg, and 10 mg lyophilized vials—with standard volumes of diluent. Researchers utilizing specialized vial masses can cross-reference their target stock concentration against our online reconstitution calculator for instant mathematical verification.

| Mass of Peptide (Vial Size) | Volume of Diluent Added | Resulting Concentration (mg/mL) | Mass per 0.1 mL (10 Units / 10 µL equivalent) | |---|---|---|---| | 2 mg | 1.0 mL | 2.0 mg/mL | 200 µg (0.2 mg) | | 2 mg | 2.0 mL | 1.0 mg/mL | 100 µg (0.1 mg) | | 2 mg | 3.0 mL | 0.67 mg/mL | 67 µg (0.067 mg) | | 5 mg | 1.0 mL | 5.0 mg/mL | 500 µg (0.5 mg) | | 5 mg | 2.0 mL | 2.5 mg/mL | 250 µg (0.25 mg) | | 5 mg | 2.5 mL | 2.0 mg/mL | 200 µg (0.2 mg) | | 5 mg | 5.0 mL | 1.0 mg/mL | 100 µg (0.1 mg) | | 10 mg | 1.0 mL | 10.0 mg/mL | 1000 µg (1.0 mg) | | 10 mg | 2.0 mL | 5.0 mg/mL | 500 µg (0.5 mg) | | 10 mg | 5.0 mL | 2.0 mg/mL | 200 µg (0.2 mg) | | 10 mg | 10.0 mL | 1.0 mg/mL | 100 µg (0.1 mg) |

When working with a high-purity batch such as Thymosin Alpha-1 5mg, adjusting solvent volume allows researchers to prepare either high-concentration stock solutions for low-volume pipetting or diluted working solutions designed to prevent volumetric measurement errors during automated assay loading.

Mathematical Formulas for Peptide Solubilization

Calculating peptide concentration relies on basic stoichiometry. The core mathematical formula connecting lyophilized mass, diluent volume, and final concentration is defined as follows:

Concentration (C) = Mass (M) / Volume (V) Where Mass (M) is expressed in milligrams (mg), Volume (V) is expressed in milliliters (mL), and Concentration (C) is expressed in mg/mL.

To calculate the total mass present in a specific draw or aliquot volume (v), the formula rearranges to: Mass per Aliquot (m) = Concentration (C) × Aliquot Volume (v)

When performing serial dilutions or converting between metric units (such as converting mg/mL to µg/µL or micromolar units), researchers must account for the molecular weight of Thymosin Alpha-1 (approximately 3,108.3 g/mol). Utilizing exact formulas ensures that molarity calculations across cell culture media formulations remain mathematically sound.

Worked Laboratory Calculation Examples

Example 1: Preparing a 2.5 mg/mL Stock Solution from a 5 mg Vial. Problem: A lab technician needs a 2.5 mg/mL stock solution of Thymosin Alpha-1 for an in vitro immune assay setup using a 5 mg vial. Calculation: V = M / C V = 5 mg / 2.5 mg/mL V = 2.0 mL Procedure: Using a precision laboratory pipette, inject exactly 2.0 mL of Bacteriostatic Water or Sterile Water for Injection down the glass side wall of the 5 mg vial. Swirl gently until dissolved. The resulting stock solution contains 2.5 mg of active peptide per milliliter (250 µg per 0.1 mL volume).

Example 2: Determining Required Pipette Volume for a 50 µg In Vitro Assay Target. Problem: Using the 2.5 mg/mL stock solution prepared in Example 1, a researcher needs to add 50 µg of Thymosin Alpha-1 to a cell culture well. Calculation: Step A: Convert target mass to milligrams: 50 µg = 0.05 mg. Step B: Calculate required volume: v = m / C v = 0.05 mg / 2.5 mg/mL v = 0.02 mL = 20 µL. Procedure: Pipette 20 µL of the reconstituted 2.5 mg/mL stock solution directly into the culture medium well to achieve the designated target mass.

Diluent Selection Criteria for In Vitro and Animal Protocols

Selecting the correct solvent is vital for maintaining chemical stability, preventing aggregation, and avoiding biological interference in downstream analytical protocols. The primary diluents utilized for reconstituting Thymosin Alpha-1 in laboratory environments include Bacteriostatic Water (0.9% Benzyl Alcohol), Sterile Water for Injection (SWFI), and Phosphate-Buffered Saline (PBS).

Bacteriostatic Water is preferred for multi-use stock vials intended for repeated sampling over extended experimental windows (up to 28 days under refrigeration at 2–8°C). The inclusion of 0.9% benzyl alcohol inhibits microbial proliferation without altering the primary peptide structure. For short-term single-use assays, cell line exposures, or sensitive electrophysiology setups where benzyl alcohol may induce cytotoxicity, Sterile Water for Injection is the standard diluent. If buffer physiological pH is strictly required for immediate assay execution, sterile PBS (pH 7.4) may be utilized, provided the peptide is completely dissolved in sterile water prior to salt concentration adjustment to avoid salting-out effects.

Standard Operating Procedure for Lyophilized Reconstitution

To prevent shear stress, peptide degradation, or contamination during reconstitution, research personnel should follow standardized aseptic laboratory handling protocols:

1. Reagent Preparation: Remove the Thymosin Alpha-1 vial and selected diluent from cold storage. Allow both vials to equilibrate to room temperature (20–25°C) for approximately 15 minutes to prevent moisture condensation upon opening.

2. Surface Decontamination: Sanitize the rubber stoppers of both the peptide vial and the solvent container using an 70% Isopropyl Alcohol (IPA) wipe within a certified laminar flow hood.

3. Pressure Equalization: Using a sterile micropipette or syringe, draw the exact pre-calculated volume of diluent. Introduce the solvent slowly by directing the stream against the interior glass wall of the vial. Avoid spraying liquid directly onto the lyophilized cake.

4. Dissolution: Allow the diluent to fully saturate the cake. Gently swirl the vial in a smooth circular motion. Never vortex or aggressively shake peptide solutions, as mechanical shear stress can cause protein denaturing, aggregation, or surface adsorption. Full dissolution typically occurs in under 60 seconds.

5. Inspection: Inspect the liquid under direct light. The solution should appear completely clear, colorless, and free of visible particulate matter or undissolved solid flakes.

Comparative Analysis: Immunomodulatory Research Peptides

In preclinical studies evaluating immunomodulatory mechanisms and cellular signalling cascades, Thymosin Alpha-1 is frequently investigated alongside other synthetic bioactive peptides. Understanding their comparative structural features and reconstitution requirements aids in experimental design.

While Thymosin Alpha-1 targets Toll-like receptor (TLR) pathways and maturation markers on dendritic cells, Thymosin Beta-4 operates primarily through actin-sequestering mechanisms to influence cell migration and tissue repair pathways. Similarly, antimicrobial and host-defense peptide models such as LL-37 display distinct hydrophobic properties requiring careful solvent selection to prevent self-association in physiological buffers. Researchers purchasing peptides for multi-target immune receptor mapping often establish batch institutional accounts through our wholesale peptide program to obtain unified lot documentation across comparative peptide series.

Analytical Quality Control and Analytical Verification

The integrity of reconstitution data depends fundamentally on the initial purity, sequence correctness, and salt content of the raw lyophilized material. Inferior manufacturing processes can leave residual counter-ions, trifluoroacetate (TFA) salts, or synthesis truncated sequences that alter peptide mass and solubility profiles.

PX1 Research ensures high experimental accuracy by subjecting every lot to stringent analytical testing. Every batch undergoes High-Performance Liquid Chromatography (HPLC) to confirm sequence purity ≥98% and Mass Spectrometry (MS) to verify precise molecular weight. Furthermore, routine bacterial endotoxin testing (LAL assay) ensures that stock materials do not introduce unwanted inflammatory responses into sensitive cell culture lines or animal models. Researchers can review, verify, and download full analytical batch records directly on our public Certificate of Analysis library.

Storage Stability and Liquid Handling Guidelines

Lyophilized Thymosin Alpha-1 exhibits superior thermodynamic stability when stored sealed at -20°C to -80°C, protected from light and atmospheric moisture. Under these conditions, the desiccated powder remains stable for up to 24 months from the date of synthesis.

Once reconstituted into aqueous liquid form, the peptide becomes susceptible to hydrolytic degradation, oxidation, and surface adsorption to container walls. Reconstituted stock solutions using Bacteriostatic Water should be stored at 2–8°C and utilized within 28 days. If long-term storage of reconstituted solution is necessary, the liquid stock must be divided into single-use micro-aliquots in low-binding polypropylene microcentrifuge tubes and stored at -80°C to avoid repeated freeze-thaw cycles. Freeze-thaw cycles cause phase separation and thermal stress that rapidly break down peptide peptide bonds, reducing active concentration.